Influenza outbreak

RECENT NEWS
The Hindu Business Line  Aug 16  Comment 
Dealth toll touches 208 so far
Benzinga  Aug 10  Comment 
Following the presentation of encouraging pre-clinical data from Novavax, Inc. (NASDAQ: NVAX)'s nanoparticle influenza vaccine, Ladenburg Thalmann upgraded shares of the company. The rating on the stock now goes from Neutral to Buy, with a $1.60...
The Hindu Business Line  Aug 10  Comment 
Health authorities are better prepared to tackle the rise in swine flu cases this year, say Government representatives, in a contrast to previous years where Government had to stockpile Oseltamivir i...
Insurance Journal  Aug 7  Comment 
Millions of hens may need to be culled in the Netherlands after traces of a potentially harmful insecticide were found in eggs, a Dutch farming group said, ratcheting up the strain on a sector still reeling from a bird flu …
GenEng News  Aug 4  Comment 
Flavonoids, compounds found in many fruits and vegetables, may work with gut microbes to prevent severe flu infections. A flavonoid-rich diet, by itself, may not offer protection, no matter how much black tea or red wine we drink, or how many...
Wall Street Journal  Jul 28  Comment 
A glut of eggs is putting pressure on suppliers and farmers who are struggling to win back business two years after the worst bout of avian influenza in U.S. history devastated the nation’s egg-laying flock.
MarketWatch  Jul 24  Comment 
Cal-Maine Foods reported earnings losses as egg demand fell, although production bounced back from the avian influenza outbreak in 2015
GenEng News  Jul 14  Comment 
An influenza vaccine trial in human volunteers has generated results that could help scientists develop a universal influenza vaccine that offers broad protection against yearly shifting viral strains. In the small-scale Phase I study, a group 2...
GenEng News  Jul 11  Comment 
Sanofi is looking to bolster its recombinant-based influenza vaccine portfolio through the acquisition of Protein Sciences for $650 million upfront and potentially up to another $100 million in milestones. The transaction, which has been approved...
GenEng News  Jul 10  Comment 
Inovio Pharmaceuticals’ synthetic plasmid DNA-based dMAb® monoclonal antibody (mAb) technology provided mice with complete protection from lethal challenge with multiple influenza A and B virus strains. The dMab platform utilizes synthetic...




 
TOP CONTRIBUTORS

Influenza, or the flu, is a common infectious disease, which can be deadly to individuals with compromised immune systems (the very young, the very old, and those with conditions such as AIDS or Cancer). However, occasionally particularly virulent strains of influenza break out that can be threatening on a much larger scale -- such as the flu epidemic of 1918 and, more recently, concerns that H5N1 "Bird Flu" or H1N1 "Swine Flu" could mutate into a highly-infectious and deadly virus. A number of pharmaceutical companies make treatments for the flu and benefit from the fear of a flu outbreak.


  • Roche Pharmaceuticals makes Tamiflu, an antiviral pill to treat the flu. In 2005, amid concerns that bird flu might pose a large threat during the winter flu season, many national governments began stocking up on Tamiflu. Chugai pharmaceuticals sells Tamiflu in Japan.
  • Novartis AG (NVS), through its acquisition of Chiron in 2006, supplies much of the traditional flu vaccine supply to the United States.
  • AstraZeneca (AZN), through recently acquired MedImmune, manufactures 'FluMist', a novel flu vaccine that is delivered via an intranasal spray rather than via an injection.

Companies with treatments for H1N1, or "Swine Flu"

In April 2009, a novel flu virus, known as "Swine Flu" because it was believed to have originated in pigs, started infecting humans. By April 28th, there were 1,300 confirmed cases of the flu, known by its scientific designation H1N1, in Mexico, and a handful in the U.S. and other parts of the world.

According to preliminary test done by the US Center for Disease Control, Roche Pharmaceuticals (RHHBY)'s Tamiflu and GlaxoSmithKline (GSK)'s Relenza are active against H1N1, although many older drugs are not. [1]

References

  1. Investors buy up shares of flu drug makers, New York Times, April 27th 2009.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki